- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Virax Biolabs receives Nasdaq minimum bid price deficiency notice | 1 | Investing.com | ||
| Fr | Virax Biolabs receives Nasdaq letter over non-compliance with minimum bid price rule | 4 | Seeking Alpha | ||
| Fr | Virax BioLabs Group Limited: Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price Deficiency | 84 | PR Newswire | LONDON, July 18, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the... ► Artikel lesen | |
| 02.07. | Virax Biolabs Group Ltd - 20-F, Annual and transition report of foreign private issuers | 2 | SEC Filings | ||
| VIRAX BIOLABS GROUP Aktie jetzt für 0€ handeln | |||||
| 13.06. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 31.03. | Virax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating | 5 | Benzinga.com | ||
| 18.03. | Virax Biolabs Enrolls First Patients in Clinical Study Assessing T cell Dysfunction in Post-acute Infection Syndromes | 135 | PR Newswire | LONDON, March 18, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on... ► Artikel lesen | |
| 18.03. | Virax Biolabs begins UK clinical study on T cell dysfunction | 1 | Investing.com | ||
| 13.03. | Virax Biolabs Presents Findings On T-Cell Dysfunction In Post-Acute Infection Syndromes | 1 | RTTNews | ||
| 13.03. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.03. | Virax Biolabs shares T-Cell dysfunction findings | 2 | Investing.com | ||
| 05.03. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 25.02. | EXCLUSIVE: Virax Biolabs Says Its Tech Fits RFK Jr.'s HHS Goals On Vaccine Transparency | 4 | Benzinga.com | ||
| 25.02. | Virax Biolabs Group Ltd - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 30.01. | Virax Biolabs Group Ltd - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 23.01. | Cosmos Health Inc.: Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait | 527 | ACCESS Newswire | CHICAGO, IL / ACCESS Newswire / January 23, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative... ► Artikel lesen | |
| 13.01. | Cosmos Health Inc.: Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries | 376 | ACCESS Newswire | CHICAGO, IL / ACCESSWIRE / January 13, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company") (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative... ► Artikel lesen | |
| 23.09.24 | Cosmos Health Inc: Cosmos Health Expands Global Presence into India, a Market with Over 1.4Bn People, Through Exclusive Agreement to Distribute Virax Biolabs' Mpox PCR Detection Kits | 252 | ACCESS Newswire | CHICAGO, IL / ACCESSWIRE / September 23, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative... ► Artikel lesen | |
| 16.09.24 | Cosmos Health Inc.: Cosmos Health Secures Exclusivity Agreement with Virax Biolabs to Distribute mpox PCR Kits across the GCC, including the UAE, Saudi Arabia, Bahrain, Kuwait, Oman, and Qatar | 290 | ACCESS Newswire | CHICAGO, IL / ACCESSWIRE / September 16, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative... ► Artikel lesen | |
| 28.08.24 | Pre-market Movers: Bolt Projects, Acri Capital Acquisition, JBDI, Virax Biolabs, Ambarella | 1.038 | AFX News | SAINT PAUL (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.50 A.M. ET).In the Green Bolt Projects Holdings, Inc. (BSLK) is up over... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 94,40 | -2,13 % | DAX-Korrektur! BioTech Im Übernahme-Modus! BioNTech, CureVac, Pfizer, Vidac Pharma und Kraft Heinz im Fokus | Die Aktienmärkte zeigen sich in Bestform: Sowohl der DAX als auch der NASDAQ 100 haben in den vergangenen Tagen Muskeln gezeigt. Angetrieben werden die Kurse vor allem von der anhaltenden Stärke der... ► Artikel lesen | |
| EVOTEC | 7,456 | +0,59 % | Evotec, Hugo Boss, Lanxess, Nagarro, SMA Solar, Zalando - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| BAVARIAN NORDIC | 24,570 | -0,32 % | Bavarian Nordic A/S: Bavarian Nordic Enters New Smallpox/Mpox Vaccine Supply Contract with European Country | Recurring order from an undisclosed European country to strengthen public preparedness.Combined with other recent orders from non-European countries, the Company has now secured above DKK 3,000 million... ► Artikel lesen | |
| ASEP MEDICAL | 6,021 | -100,00 % | Asep Medical validiert seinen Sepset(ER) Diagnosetest bei Patienten in der führenden wissenschaftlichen Fachzeitschrift Nature Communications. | 27. Mai 2025 / IRW-Press / Asep Medical Holdings Inc. ("Asep Medical" oder das "Unternehmen") (CSE: ASEP) (OTCQB: SEPSF) (FWB: JJ80) freut sich
bekanntzugeben, dass seine Tochtergesellschaft... ► Artikel lesen | |
| EMERGENT BIOSOLUTIONS | 6,000 | +0,67 % | Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025 | ||
| GINKGO BIOWORKS | 8,700 | 0,00 % | Ginkgo Bioworks launches cost-effective ADME profiling service | ||
| GENPREX | 1,820 | -100,00 % | Genprex, Inc.: Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting | Both REQORSA Alone and in Combination with LUMAKRAS® Demonstrated Robust Anti-Tumor Effects in Ras Inhibitor Resistant Non-Small Cell Lung Cancer
AUSTIN, Texas... ► Artikel lesen | |
| PALISADE BIO | 0,750 | +0,54 % | Palisade Bio, Inc.: Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn's Disease and Ulcerative Colitis | Study met its primary endpoints of safety, tolerability, and pharmacokinetics (PK) No serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs... ► Artikel lesen | |
| GRITSTONE BIO | 0,016 | -100,00 % | Gritstone bio, Inc. - 15-12G, Securities registration termination | ||
| SIGA TECHNOLOGIES | 6,605 | -1,42 % | Dividendenbekanntmachungen (15.05.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) 1&1 AG DE0005545503 - 0,05 EUR A10 NETWORKS INC US0021211018 0,06 USD 0,0536 EUR ADMIRAL GROUP PLC GB00B02J6398 0,914 GBP 1,0846... ► Artikel lesen | |
| GEOVAX LABS | 2,685 | -100,00 % | GeoVax Labs, Inc. - 8-K, Current Report | ||
| ANNOVIS BIO | 2,320 | +1,75 % | Annovis Bio Inc.: Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance | MALVERN, Pa., June 19, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative... ► Artikel lesen | |
| SYROS PHARMACEUTICALS | 0,108 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 25.03.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 25.03.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 25.03.2025.ISIN NameCA05553A1075 THE... ► Artikel lesen | |
| HUMACYTE | 2,335 | -3,51 % | Humacyte, Inc: Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update | - Commenced market launch and first commercial sales of Symvess (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma - - Total revenues of $517,000 for quarter... ► Artikel lesen | |
| SAGIMET BIOSCIENCES | 8,000 | -1,23 % | Sagimet Biosciences Inc.: Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis | Denifanstat met all primary and secondary endpoints versus placebo Denifanstat was well tolerated Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to... ► Artikel lesen |
VIRAX BIOLABS GROUP LIMITED gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +7,61 % bei einem Aktienkurs von 0,990 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VIRAX BIOLABS GROUP LIMITED finden Sie auf Wallstreet Online.